Other Conditions
Latest Literature on Benefits of Ketamine
Saligan et al. (2016) found that a double-blind, placebo-controlled, crossover study in bipolar disorder showed ketamine significantly reduced fatigue scores compared to placebo.
Kopra et al. (2021) conducted a systematic review on the effects of ketamine on inflammation and kynurenine pathway in depression. Their findings suggest that ketamine has anti-inflammatory effects in some depressed patients. Future research should examine central nervous system markers and clinical relevance of these changes. Boldrini et al. (2021) discussed how COVID-19 affects the brain, with some patients experiencing cognitive deficits, anxiety, depression, and seizures. The understanding of COVID-19 brain damage could lead to interventions to reduce neuropsychiatric symptoms, which may include ketamine therapy as an NMDA receptor antagonist.
Smalheiser (2020) suggested that ketamine therapy could be a potential treatment for Alzheimer's disease, based on its similar pharmacologic profile to memantine, one of the most commonly prescribed drugs for Alzheimer's patients. The existing literature provides a strong scientific rationale for testing the precognitive effects of ketamine in Alzheimer's patients.
See for more literature on Depression, Anxiety, Substance Abuse, Other Mental Health Conditions, Chronic Pain.
Other useful articles